| 영문 | TNM staging system | 한글 | 종양병기분류계통 |
|---|---|---|---|
| 설명 | 종양의 병기(stage)를 결정하는 한 방법. T는 Tumor(종양)를 뜻하며 원발병터의 크기, 주위조직으로의 침윤정도 등에 따라 T1, T2, T3, T4(숫자가 높을 수록 주위로 침윤이 많다) 등으로 나눈다. N은 Node(림프절)를 뜻하며 침범된 림프절의 갯수, 크기, 위치 등에 따라 N1, N2, N3 등으로 나눈다. M은 Metastasis(전이)를 뜻하며 원격전이의 유무에 따라 M0, M1 등으로 나눈다. 이상의 방법으로 T, N, M이 결정되면 이들을 조합하여 최종적인 병기를 결정한다. 이렇게 결정된 병기는 치료 방침 결정과 예후 판단에 매우 중요하다. |
||
| NAHPA | National Association of Hospital Purchasing Agents |
|---|---|
| OHA | oral hypoglycemic agents |
| CS | calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ... |
| CTT | cefotetan; central tegmental tract; central transmission time; compressed tablet triturate; computer... |
| CVO | central vein occlusion; central venous oxygen; Chief Veterinary Officer; credentialing verification ... |
| syndrome, nervous colon | See Syndrome, irritable bowel. (12 Dec 1998) |
|---|---|
| internal carotid (nervous) plexus | An autonomic plexus surrounding the internal carotid artery in the carotid canal and cavernous sinus, and sending branches to the tympanic plexus, sphenopalatine ganglion, abducens and oculomotor nerves, the cerebral vessels, and the ciliary ganglion. Synonym: internal carotid venous plexus. (05 Mar 2000) |
| abortifacient agents | Chemical substances that interrupt pregnancy after implantation. (12 Dec 1998) |
| abortifacient agents, non-steroidal | Non-steroidal chemical compounds with abortifacient activity. (12 Dec 1998) |
| abortifacient agents, steroidal | Steroidal compounds with abortifacient activity. (12 Dec 1998) |
| adrenergic agents | Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (12 Dec 1998) |
| alkylating agents | Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agent, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (12 Dec 1998) |
| anti-allergic agents | Agents that are used to treat allergic reactions. most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (12 Dec 1998) |
| anti-anxiety agents | Agents that alleviate anxiety, tension, and neurotic symptoms, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anaesthesia adjuvants. Adrenergic beta-antagonists are commonly used in the symptomatic treatment of anxiety but are not included here. Substances with a benzodiazepine ring structure widely used to treat anxiety and neuroses. Drugs in this class also generally have sedative or weak hypnotic properties and may be effective as muscle relaxants, anticonvulsants, and anaesthesia adjuvants. (12 Dec 1998) |
| anti-arrhythmia agents | Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (12 Dec 1998) |
| anti-asthmatic agents | Drugs that are used to treat asthma. (12 Dec 1998) |
| anticarcinogenic agents | Agents that reduce the frequency or rate of spontaneous or induced tumours independently of the mechanism involved. They differ from antineoplastic agent in that they prevent neoplasms from forming. The anticarcinogenic substances can be divided into three categories. The first consists of compounds that prevent the formation of carcinogens from precursor substances. The second group consists of "blocking agents" which inhibit carcinogenesis by preventing carcinogenic agents from reaching or reacting with critical target sites in the tissues. The third group is the "suppressor agents" which act by suppression of expression of neoplasia in cells previously exposed to carcinogens that would otherwise cause neoplasms. (12 Dec 1998) |
| anticestodal agents | Agents used to treat tapeworm infestations in man or animals. (12 Dec 1998) |
| anticholesteraemic agents | Substances that promote a reduction of blood cholesterol levels. (12 Dec 1998) |
| anti-coagulant agents | Medications, like heparin, used as blood-thinners to prevent blood clots and to maintain open blood vesssels. (12 Dec 1998) |